Search details
1.
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.
Br J Surg
; 111(2)2024 Jan 31.
Article
in English
| MEDLINE | ID: mdl-38381934
2.
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Oncologist
; 28(4): e205-e211, 2023 04 06.
Article
in English
| MEDLINE | ID: mdl-36905578
3.
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Radiology
; 299(1): 109-119, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33497314
4.
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407).
Oncologist
; 25(9): 745-e1265, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32045050
5.
Atypical patterns of response and progression in the era of immunotherapy combinations.
Future Oncol
; 16(23): 1707-1713, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32687405
6.
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Br J Cancer
; 121(7): 537-544, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31477779
7.
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Oncologist
; 24(1): 38-46, 2019 01.
Article
in English
| MEDLINE | ID: mdl-29794066
8.
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Future Oncol
; 13(7): 615-624, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27802780
9.
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
Expert Opin Emerg Drugs
; 21(3): 267-82, 2016 Sep.
Article
in English
| MEDLINE | ID: mdl-27578253
10.
Fcγ receptors and immunomodulatory antibodies in cancer.
Nat Rev Cancer
; 24(1): 51-71, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38062252
11.
Druggable Targets in Cytokine Release Syndromes.
Clin Cancer Res
; 29(21): 4320-4322, 2023 11 01.
Article
in English
| MEDLINE | ID: mdl-37656058
12.
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Clin Cancer Res
; 29(12): 2250-2265, 2023 06 13.
Article
in English
| MEDLINE | ID: mdl-36749875
13.
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Nat Cancer
; 3(11): 1336-1350, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36302895
14.
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Lancet Respir Med
; 9(6): 613-621, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33836153
15.
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Eur J Cancer
; 155: 168-178, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34385069
16.
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Lancet Diabetes Endocrinol
; 9(8): 491-501, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34118198
17.
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
J Clin Oncol
; 39(20): 2304-2312, 2021 07 10.
Article
in English
| MEDLINE | ID: mdl-33945297
18.
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Trends Cancer
; 6(3): 181-191, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32101722
19.
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial.
Mol Cancer Ther
; 19(1): 312-317, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31540966
20.
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Clin Cancer Res
; 26(8): 1846-1855, 2020 04 15.
Article
in English
| MEDLINE | ID: mdl-31757877